Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. (journals.asm.org)

Authors: Patel M … Gheyas F Journal: Antimicrobial Agents and Chemotherapy Published: 2026-03-04 DOI: https://doi.org/10.1128/aac.01313-25